Contrasting Lucid Diagnostics (NASDAQ:LUCD) & OraSure Technologies (NASDAQ:OSUR)

Lucid Diagnostics (NASDAQ:LUCDGet Rating) and OraSure Technologies (NASDAQ:OSURGet Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Lucid Diagnostics and OraSure Technologies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucid Diagnostics 0 0 6 0 3.00
OraSure Technologies 0 1 2 0 2.67

Lucid Diagnostics presently has a consensus target price of $12.33, indicating a potential upside of 399.33%. OraSure Technologies has a consensus target price of $12.83, indicating a potential upside of 89.00%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than OraSure Technologies.

Insider and Institutional Ownership

98.7% of OraSure Technologies shares are held by institutional investors. 1.7% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Lucid Diagnostics and OraSure Technologies’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lucid Diagnostics $500,000.00 184.92 -$28.08 million N/A N/A
OraSure Technologies $233.67 million 2.15 -$23.00 million ($0.32) -21.22

OraSure Technologies has higher revenue and earnings than Lucid Diagnostics.

Profitability

This table compares Lucid Diagnostics and OraSure Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lucid Diagnostics N/A N/A N/A
OraSure Technologies -9.84% -5.83% -5.00%

Summary

Lucid Diagnostics beats OraSure Technologies on 7 of the 11 factors compared between the two stocks.

Lucid Diagnostics Company Profile (Get Rating)

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW YORK.

OraSure Technologies Company Profile (Get Rating)

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.

Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.